Bergenin inhibits hepatic fat deposition by activating the AMPK signaling pathway, thereby attenuating alcoholic liver disease
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113169 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Fengyue Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmacology for Prevention and Treatment of High Incidence Diseases in Guangxi Higher Education Institutions, Guilin Medical Unive…. Hauptthemen laut MEDLINE: Mice, Inbred C57BL, Liver Diseases, Alcoholic, Signal Transduction, Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Guilin Medical University, National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province.
Abstract (Originalsprache)
Alcoholic liver disease (ALD) is a prevalent liver condition that arises from prolonged and excessive alcohol intake. Bergenin (BER) is an effective phytotherapeutic agent that exhibits pharmacological properties, including anti-inflammatory and anti-oxidative effects. To establish an in vivo model of ALD, C57BL/6 mice were continuously fed a high-fat diet (HFD) and administered alcohol gavage for 8 weeks, while concurrently administering BER and evaluated for therapeutic effects. After modeling, the therapeutic effects of BER were evaluated by observing histopathological changes and the detection of relevant biochemical indicators in mice. In addition, RNA sequencing of liver tissues was performed to analyze differentially expressed genes and to investigate the associated signaling pathways in order to elucidate the protective mechanisms of BER. These differentially expressed genes were mainly enriched in lipid metabolism pathways and the cytochrome P450 metabolism of exogenous substances. Subsequently, HepG2 was co-treated with sodium oleate (NaOA) and ethanol to establish an in vitro model, and the specific mechanism by which BER ameliorates ALD was further analyzed in depth. AMPK inhibitor, Compound C (CC), was demonstrated to significantly inhibit the regulation of lipid metabolism by BER in vitro. Finally, the differentially expressed genes selected were validated through qRT-PCR and Western blot analysis. Collectively, our findings revealed that BER effectively alleviated liver injury caused by alcohol and HFD in mice, significantly suppressing lipid deposition in ALD, enhancing alcohol metabolism, and mitigating oxidative stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pharmacology for Prevention and Treatment of High Incidence Diseases in Guangxi Higher Education Institutions, Guilin Medical University, Guilin 541199, Guangxi, China.
- Affiliated Hospital of Guilin Medical University , Guilin Medical University, Guilin 541001, Guangxi, China.
- Key Laboratory of Pharmacology for Prevention and Treatment of High Incidence Diseases in Guangxi Higher Education Institutions, Guilin Medical University, Guilin 541199, Guangxi, China. Electronic address: kefengzhang@…
- Key Laboratory of Pharmacology for Prevention and Treatment of High Incidence Diseases in Guangxi Higher Education Institutions, Guilin Medical University, Guilin 541199, Guangxi, China. Electronic address: yagao@glmc.e…
Förderung
- Guilin Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
Zitieren
APA
Guo, F., Zheng, H., Cao, H., Wang, Y., Zhi, Y., Liu, H., Li, B., Wu, J., Zhang, K., & Gao, Y. (2024). Bergenin inhibits hepatic fat deposition by activating the AMPK signaling pathway, thereby attenuating alcoholic liver disease. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113169
Vancouver
Guo F, Zheng H, Cao H, Wang Y, Zhi Y, Liu H, et al. Bergenin inhibits hepatic fat deposition by activating the AMPK signaling pathway, thereby attenuating alcoholic liver disease. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113169
BibTeX
@article{Guo2024,
author = {Guo, Fengyue and Zheng, Huaping and Cao, Houkang and Wang, Yongwang and Zhi, Yueping and Liu, Haiping and Li, Bo and Wu, Jianzhao and Zhang, Kefeng and Gao, Ya},
title = {Bergenin inhibits hepatic fat deposition by activating the AMPK signaling pathway, thereby attenuating alcoholic liver disease},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113169}
}
EUVIMED